Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Multicenter Phase II Trial With Gemcitabine Plus Sorafenib Versus Gemcitabine Plus Placebo in Patients With Chemo-naive Advanced or Metastatic Adenocarcinoma of the Biliary Tract

NCT00661830 is registered in ClinicalTrials.gov with PD Dr Markus Möhler as lead sponsor.

NCT NCT00661830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00661830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Multicenter Phase II Trial With Gemcitabine Plus Sorafenib Versus Gemcitabine Plus Placebo in Patients With Chemo-naive Advanced or Metastatic Adenocarcinoma of the Biliary Tract
Lead sponsor
PD Dr Markus Möhler
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2008
Completion date
June 30, 2010
Enrollment
103 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma